Can Directors Be Held Liable for Drug Quality Issues? Supreme Court Clarifies
LALANKUMAR SINGH & ORS. VERSUS STATE OF MAHARASHTRA
Listen to this judgment
• 4 min readKey Takeaways
• A court cannot hold directors liable for a company's drug quality issues merely because they are directors.
• Section 34 of the Drugs and Cosmetics Act requires specific averments regarding a director's role in the company's operations.
• Vicarious liability under Section 34 arises only if a director was in charge of and responsible for the company's conduct at the time of the offence.
• Merely being a director does not automatically imply responsibility for day-to-day operations or compliance with drug standards.
• The order of issuance of process by a magistrate must reflect application of mind and sufficient grounds for proceeding against the accused.
Introduction
The Supreme Court of India recently addressed the issue of director liability in the context of drug quality standards under the Drugs and Cosmetics Act, 1940. The case of Lalankumar Singh & Ors. vs. State of Maharashtra raised critical questions about the extent to which directors can be held accountable for the actions of their companies, particularly in cases involving the manufacture of substandard drugs. This judgment clarifies the legal standards required for establishing such liability and the necessary averments that must be made in complaints against directors.
Case Background
The appellants in this case, Lalankumar Singh and others, are directors of M/s Cachet Pharmaceuticals Private Ltd. (CPPL), which was granted permission to manufacture 'Hemfer Syrup'. The case arose when a Drugs Inspector purchased samples of the syrup and found them to be of substandard quality, specifically noting that the content of Cyanocobalamin was below the permissible limit. Following this, the Drug Inspector initiated legal proceedings against CPPL and its directors under the Drugs and Cosmetics Act.
The Chief Judicial Magistrate (CJM) issued summons to the directors, which led to a series of legal challenges, including a Criminal Revision Petition and a Criminal Writ Petition, both of which were dismissed by the lower courts. The appellants contended that the complaints against them lacked specific allegations regarding their involvement in the alleged offence, which is a prerequisite for establishing liability under Section 34 of the Act.
What The Lower Authorities Held
The learned CJM issued summons based on the complaint filed by the Drug Inspector, which alleged that the directors were responsible for the manufacture and sale of the substandard drug. The Sessions Judge upheld the CJM's order, stating that the complaint contained sufficient averments to proceed against the directors. The Bombay High Court also dismissed the appellants' writ petition, asserting that the directors were involved in the business operations of CPPL and thus could be held liable.
The Court's Reasoning
The Supreme Court, while hearing the appeal, emphasized the necessity of specific averments in the complaint against the directors. It reiterated that Section 34 of the Drugs and Cosmetics Act imposes liability only on those who were in charge of and responsible for the conduct of the company's business at the time the offence was committed. The Court highlighted that simply being a director does not automatically confer liability; there must be clear allegations regarding the director's role in the company's operations.
The Court referred to previous judgments that established the principle that vicarious liability cannot be imposed without specific averments detailing how a director was responsible for the company's conduct. The Court noted that the complaint against the appellants lacked such specific allegations, rendering it insufficient to establish their liability.
Statutory Interpretation
The judgment involved a detailed interpretation of Section 34 of the Drugs and Cosmetics Act, which outlines the conditions under which a director can be held liable for offences committed by a company. The Court clarified that the provision requires a clear demonstration of the director's involvement in the company's operations, particularly at the time of the alleged offence. The Court also examined the relevant rules under the Drugs and Cosmetics Act, emphasizing the need for compliance with manufacturing standards and the responsibilities of technical staff.
CONSTITUTIONAL OR POLICY CONTEXT
While the judgment primarily focused on statutory interpretation, it also touched upon broader principles of criminal liability and the importance of ensuring that individuals are not unjustly prosecuted based solely on their corporate titles. The Court's ruling reinforces the need for due process and the protection of individuals from vicarious liability without adequate evidence of their involvement in the alleged wrongdoing.
Why This Judgment Matters
This ruling is significant for legal practice as it clarifies the standards for holding directors liable under the Drugs and Cosmetics Act. It underscores the importance of specific allegations in complaints against directors and sets a precedent for future cases involving corporate liability. Legal practitioners must ensure that complaints against directors contain detailed averments regarding their roles and responsibilities to withstand judicial scrutiny.
Final Outcome
The Supreme Court allowed the appeal, quashing the orders of the CJM and the Sessions Judge, and dismissed the complaint against the appellants. The Court emphasized that the complaint must proceed against the remaining accused in accordance with the law, but the appellants could not be held liable based on the existing allegations.
Case Details
- Case Title: LALANKUMAR SINGH & ORS. VERSUS STATE OF MAHARASHTRA
- Citation: 2022 INSC 1061
- Court: IN THE SUPREME COURT OF INDIA
- Date of Judgment: 2022-10-11
